Supplementary MaterialsSupplementary Dataset 1 41598_2019_42237_MOESM1_ESM. mediated by its effect on tumor cells and tumor-associated macrophages, and not directly over T cells. Overall, our results indicate that selective HDAC6i could be used as immunological priming brokers to sensitize immunologically cold tumors and subsequently improve ongoing immune check-point blockade therapies. Introduction Most standard therapies for cancer patients… Continue reading Supplementary MaterialsSupplementary Dataset 1 41598_2019_42237_MOESM1_ESM. mediated by its effect on tumor